LOWELL, Mass., May 22, 2018 /PRNewswire/ -- Anuncia, Inc., a privately-held company focused on better treatment of hydrocephalus and cerebrospinal fluid dysfunctions, announced, today, the successful ...
98% of placements using SOLOPASS® 2.0 entered the ventricular system, versus only 10% of freehand placements. 86% of placements using SOLOPASS® 2.0 accurately reached the ipsilateral frontal horn ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results